Monto, A. S. (2021). The Future of SARS-CoV-2 Vaccination—Lessons from Influenza. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMp2113403

Maier, B. F., Wiedermann, M., Burdinski, A., Klamser, P., Jenny, M. A., Betsch, C., & Brockmann, D. (2021). Germany’s current COVID-19 crisis is mainly driven by the unvaccinated (p. 2021.11.24.21266831). https://doi.org/10.1101/2021.11.24.21266831

Regev-Yochay, G., Gonen, T., Gilboa, M., Mandelboim, M., Indenbaum, V., Amit, S., Meltzer, L., Asraf, K., Cohen, C., Fluss, R., Biber, A., Nemet, I., Kliker, L., Joseph, G., Doolman, R., Mendelson, E., Freedman, L. S., Harats, D., Kreiss, Y., & Lustig, Y. (2022). 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC (p. 2022.02.15.22270948). medRxiv. https://doi.org/10.1101/2022.02.15.22270948

🇺🇦 Meaghan Kall. (2022, January 27). NEW: 🏴󠁧󠁢󠁥󠁮󠁧󠁿 Vaccine effectiveness (symptomatic infection) data for BA.2 {Omicron’s more infectious sister} NO difference in VE between Omicron (BA.1) and BA.2 Possibly even higher VE for BA.2 but estimates overlap See full thread 🧵 from @freja_kirsebom https://t.co/bJ7uCn2cGV [Tweet]. @kallmemeg. https://twitter.com/kallmemeg/status/1486821549458001927

Eric Topol. (2021, April 23). Just published @TheLancet: Effect of vaccine in >23,000 health care workers https://t.co/ohy3VyHM3C Dose response: No vaccine 977 infections; 1 dose 71 infections; 2 doses 9 infections (14|8|4 per 10,000 person-days) "can prevent both symptomatic and asymptomatic infection " https://t.co/EybVBFmXrU [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1385729322472730626

Mahase, E. (2022). Omicron sub-lineage BA.2 may have “substantial growth advantage,” UKHSA reports. BMJ, 376, o263. https://doi.org/10.1136/bmj.o263

Scientists try to pinpoint why rapid Covid tests are missing some cases. (2022, January 6). STAT. https://www.statnews.com/2022/01/06/scientists-try-to-pinpoint-why-rapid-covid-tests-are-missing-cases/

Meaghan Kall. (2021, November 15). There are 2 other impressive conclusions from this study: 1. Comparing vaccine effectiveness of booster vs “fully vaxxed” as the baseline. Booster ADDS 81-85% protection against symptomatic infection ON TOP of what you already had from your primary (2-dose) vaccination https://t.co/5EO7m6GHTZ [Tweet]. @kallmemeg. https://twitter.com/kallmemeg/status/1460207567070769156

Kennedy-Shaffer, L., Kahn, R., & Lipsitch, M. (2021). Estimating Vaccine Efficacy Against Transmission via Effect on Viral Load. Epidemiology (Cambridge, Mass.), 32(6), 820–828. https://doi.org/10.1097/EDE.0000000000001415

Griffin, S. (2021). Covid-19: China’s CoronaVac vaccine offers 83.5% protection against symptomatic infection, interim analysis finds. BMJ, 374, n1755. https://doi.org/10.1136/bmj.n1755

“Cases Rising Rapidly among Those with Incomplete Vaccinations.” Accessed June 15, 2021. https://covid.joinzoe.com/post/cases-rising-rapidly-among-those-with-incomplete-vaccinations.

Covid variants: How much protection do the different vaccines offer? (2021, June 3). The Guardian. http://www.theguardian.com/world/2021/jun/03/covid-variants-delta-alpha-how-much-protection-vaccines

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021). Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine, 1–7. https://doi.org/10.1038/s41591-021-01377-8

A Marm Kilpatrick. (2021, February 9). Vaccine efficacy in blocking infection & transmission (I think) We can now estimate the (minimum) reduction in transmission from the Moderna vaccine. Thread tl;dr Moderna vaccine blocks >90% (87-93%) of infections & 91% (89-94%) of transmission. *Critiques welcome! Https://t.co/GjQIo3v4oe [Tweet]. @DiseaseEcology. https://twitter.com/DiseaseEcology/status/1359213735424872450

Pullano, G., Di Domenico, L., Sabbatini, C. E., Valdano, E., Turbelin, C., Debin, M., Guerrisi, C., Kengne-Kuetche, C., Souty, C., Hanslik, T., Blanchon, T., Boëlle, P.-Y., Figoni, J., Vaux, S., Campèse, C., Bernard-Stoecklin, S., & Colizza, V. (2021). Underdetection of cases of COVID-19 in France threatens epidemic control. Nature, 590(7844), 134–139. https://doi.org/10.1038/s41586-020-03095-6

ReconfigBehSci on Twitter: ‘RT @d_spiegel: Excellent new Covid RED dashboard from UCL https://t.co/wHMG8LzTUb Would be good to also know (a) how many contacts isolate…’ / Twitter. (n.d.). Retrieved 6 March 2021, from https://twitter.com/SciBeh/status/1323316018484305920

Matrajt, Laura, Julia Eaton, Tiffany Leung, und Elizabeth R. Brown. „Vaccine Optimization for COVID-19: Who to Vaccinate First?“ Science Advances 7, Nr. 6 (1. Februar 2020): eabf1374. https://doi.org/10.1126/sciadv.abf1374.

Nogrady, B. (2020). What the data say about asymptomatic COVID infections. Nature, 587(7835), 534–535. https://doi.org/10.1038/d41586-020-03141-3

Hamzelou, J. (2020, June 17). How many of us are likely to have caught the coronavirus so far? New Scientist. https://www.newscientist.com/article/mg24632873-000-how-many-of-us-are-likely-to-have-caught-the-coronavirus-so-far/

Azad, A. (2020, May 22). CDC estimates that 35% of coronavirus patients don’t have symptoms. CNN. https://www.cnn.com/2020/05/22/health/cdc-coronavirus-estimates-symptoms-deaths/index.html

Koerth, M. (2020, March 31). Why It’s So Freaking Hard To Make A Good COVID-19 Model. FiveThirtyEight. https://fivethirtyeight.com/features/why-its-so-freaking-hard-to-make-a-good-covid-19-model/

Smith, C. (2020, May 12). Hospital staff carrying COVID-19.https://www.thenakedscientists.com/articles/science-news/hospital-staff-carrying-covid-19

Buitrago-Garcia, D. C., Egli-Gany, D., Counotte, M. J., Hossmann, S., Imeri, H., Salanti, G., & Low, N. (2020). The role of asymptomatic SARS-CoV-2 infections: Rapid living systematic review and meta-analysis [Preprint]. Epidemiology. https://doi.org/10.1101/2020.04.25.20079103

Gudbjartsson, D. F., Helgason, A., Jonsson, H., Magnusson, O. T., Melsted, P., Norddahl, G. L., Saemundsdottir, J., Sigurdsson, A., Sulem, P., Agustsdottir, A. B., Eiriksdottir, B., Fridriksdottir, R., Gardarsdottir, E. E., Georgsson, G., Gretarsdottir, O. S., Gudmundsson, K. R., Gunnarsdottir, T. R., Gylfason, A., Holm, H., … Stefansson, K. (2020). Spread of SARS-CoV-2 in the Icelandic Population. New England Journal of Medicine, NEJMoa2006100. https://doi.org/10.1056/NEJMoa2006100

Danis, K., Epaulard, O., Bénet, T., Gaymard, A., Campoy, S., Bothelo-Nevers, E., Bouscambert-Duchamp, M., Spaccaferri, G., Ader, F., Mailles, A., Boudalaa, Z., Tolsma, V., Berra, J., Vaux, S., Forestier, E., Landelle, C., Fougere, E., Thabuis, A., Berthelot, P., … Bag, B. C. (2020). Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020. Clinical Infectious Diseases, ciaa424. https://doi.org/10.1093/cid/ciaa424

Bi, Q., Wu, Y., Mei, S., Ye, C., Zou, X., Zhang, Z., Liu, X., Wei, L., Truelove, S. A., Zhang, T., Gao, W., Cheng, C., Tang, X., Wu, X., Wu, Y., Sun, B., Huang, S., Sun, Y., Zhang, J., … Feng, T. (2020). Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: A retrospective cohort study. The Lancet Infectious Diseases, S1473309920302875. https://doi.org/10.1016/S1473-3099(20)30287-5

Dr Muge Cevik on Twitter

Steinbrook, R. (2020). Contact Tracing, Testing, and Control of COVID-19—Learning From Taiwan. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2020.2072